Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2.

Autor: Jordan JT; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Orr CC; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Thalheimer RD; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Cambillo JV; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Beauchamp RL; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA., Shaikh G; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA., Muzikansky A; Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Stemmer-Rachamimov A; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Giovannini M; Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA and Jonsson Comprehensive Cancer Center (JCCC), University of California Los Angeles, Los Angeles, CA, USA., Kalamarides M; Department of Neurosurgery, Hopital Pitie-Salpetriere, Sorbonne Université, Paris, France., Barker FG 2nd; Neurosurgical Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Ramesh V; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA., Plotkin SR; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Publikováno v: Neuro-oncology advances [Neurooncol Adv] 2023 Apr 17; Vol. 5 (1), pp. vdad041. Date of Electronic Publication: 2023 Apr 17 (Print Publication: 2023).